Global Hemophehilia Treatment Market Calculated to Value Over US$ 15 Billion by 2026 End

  • 07 Jun 2019

The global hemophehilia treatment market is forecasted to value over US$ 15 billion by the end of 2026 and grow at a CAGR of over 5% during the forecast period of 2019-2026.

Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood clotting ability is impaired. Basically, due to lack of sufficient amount of blood-clotting proteins or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX and hemophilia C occurs due to lack of factor XI. Utilization of innovative techniques and technological advancements are the driving force for the growth of the global market. According to World Federation of Hemophilia (WFH), hemophilia A affects 1 in 5000 males that take birth. It is estimated that around 75% of the global hemophilia patient pool has no proper access to treatment. Therefore, in order to provide consistent treatment for patients, agencies like Hemophilia Association of America (HAA) have pursued key market players for the introduction of co-pay assistance initiatives. For instance, CSL Behring made a donation of 1.5 million units of their anti-hemophilic agents on world hemophilia day which is on April 17. At present, there is no cure present for hemophilia A and treatments are primarily conducted to manage the disease. Due to the lack of provision of medical needs and monopolistic opportunities for manufacturers, there is a huge demand for effective hemophilia management. Also, due to the presence of limited amount of therapies and regulatory authorities facing a huge task on the treatment of these disorders, the research and development also get a boost so that they can identify curative agents which in turn will help to accelerate growth during the forecast period.   

Insights on Hemophilia Treatment Market:
By Region

•    North America
•    Europe
•    Asia Pacific
•    Latin America
•    Rest of the world
North America is expected to be a major shareholder of the global market due to high awareness and supportive regulatory policies. European region follows North America and is expected to have a significant share during the forecast period. Asia Pacific regions are expected to experience a rapid market growth rate due to changing healthcare policies and increasing awareness. Latin America and the rest of the world are both expected to possess a small fraction of the global market due to lack of awareness. 

By Type of Product
•    Recombinant clotting factors concentrate
•    Plasma derived factor concentrates

 By Type of Disease
•    Hemophilia A 
•    Hemophilia B
•    Hemophilia C
Hemophilia A treatments are expected to grow at a higher rate in the market as compared to hemophilia B and hemophilia C during the forecast period due to the prevalence of the disease throughout the world.

By End User
•    Hospital
•    Clinic
•    Others
The hospital segment is expected to get a boost in the market growth during the forecast period as more and more multi-speciality hospitals are being built which provide hemophilia treatments and has an infrastructural advantage over the clinics and this trend will be observed in the North American and European regions due to the high spending capacity of the general population. On the other hand, clinic treatments will obtain a rapid growth rate in emerging economies due to lesser treatment cost as compared to hospitals.

Competitive Landscape:
•    Baxter International Inc.
•    Bayer AG
•    Pfizer
•    Biogen Idec Inc.
Baxter International Inc. has obtained approval for Obizur, which is a recombinant concentrate for treating hemophilia A which will help them get some market share during the forecast period because it is the first recombinant porcine FVIII treatment for acquired hemophilia A. Bayer has got their injection named Jivi FDA-approved last year for treatment for patients aged 12 or above which will help replace reduced or missing factor VIII and this too will help them acquire a good growth rate during the forecast period. Pfizer has initiated a phase-3 study for safety evaluation of current therapy of factor IX prophylaxis replacement therapy which will help them gain some traction in the market during the forecast period.

FutureWise Key Takeaways:
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study:
•    To provide with an exhaustive analysis on the global hemophilia treatment market by region, by type of product, by type of disease, by end user, by market players
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com